Skip to main content
Fig. 1 | Trials

Fig. 1

From: The effects of esketamine and treatment expectation in acute major depressive disorder (Expect): study protocol for a pharmacological fMRI study using a balanced placebo design

Fig. 1

Study design. One hundred seventy-six patients with acute MDD will be recruited (d-3), undergo baseline assessment (d01), female participants of child bearing age will undergo a serum pregnancy test (d-3). At d1, patients will be randomized into 4 groups with the factors treatment (esketamine/placebo) and expectation (high/low). They will take part in two fMRI studies, rsfMRI, DTI and T1 scanning. Clinical outcomes will be assessed after 2 h, 4 h (all d1), 24 h (d2), 3d and 7d post treatment. Urine pregnancy tests will be performed at day 28

Back to article page

Trials

ISSN: 1745-6215